Serum Institute pauses COVID-19 vaccine trials in India

New Delhi: Serum Institute of India, which is manufacturing the coronavirus vaccine Covishield being developed by the Oxford University along with pharma major AstraZenca, said it will stop the Phase 3 trials that were to begin in India next week.

The vaccine trial was stopped across four nations as a precautionary measure after one of the recipients in the U.K showed some potentially adverse symptoms.

The Serum Institute was issued a showcause notice by the country's drug controller DCGI on Wednesday, where it was questioned why it was continuing the trials in India even though it has been stopped elsewhere.

The DCGI also questioned why it has not received a report detailing the symptoms of the patient in the U.K.

"We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials," read a statement from the Serum Institute, which was still doing the groundwork for the trial including listing volunteers.

The trials were to be held on 1,600 volunteers across 17 sites in India and were expected to begin next week. Asianet Online